#City Therapeutics

17 Oct 2026

City Therapeutics Raises $200 Million IPO to Fund RNAi Drugs Beyond the Liver

The biotech sold 11.1 million shares at $18 each, raising $200 million to push its RNA interference pipeline beyond liver‑targeted therapies.

Read more